Research

Research

Current Clinical Trials at Comprehensive Cardiology

Atrial Fibrillation

ORBIT-AFII Trial (ENROLLMENT CLOSED)

A Phase 4 Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (Data collection from office records over 24 months).
Principle Investigator: Rakesh Shah, MD, F.A.C.C.
Sponsor: Astra Zeneca

Coronary Artery Disease Outcome Trials

COMPASS (BAY 59-7939/15786 Trial) (ENROLLMENT CLOSED)

A Randomized Controlled trial of rivaroxaban for the prevention of major cardiovascular events in patients with coronary or peripheral artery disease (COMPASS-Cardiovascular Outcomes for People using Anticoagulation Strategies).
Principle Investigator: Ronald Fields, M.D., F.A.C.C.
Sponsor: Bayer HealthCare Pharmaceuticals, Inc.

DECLARE TIMI-58 (D1693C00001) (ENROLLMENT CLOSED)

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10mg Once Daily on the incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients with Type 2 Diabetes
Principle Investigator: Rakesh Shah, MD, F.A.C.C.
Sponsor: Astra Zeneca

CAMELLIA TIMI-61 (ADP356-G000-401) (ENROLLMENT CLOSED)

A Randomized, Double-Blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment with BELVIQ on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects with Cardiovascular Disease or Multiple Cardiovascular Risk Factors”
Principle Investigator: Rakesh Shah, MD, F.A.C.C.
Sponsor: Eisai Inc.

Dal-GENE-E Trial: (ENROLLMENT OPEN)

A phase III, double-blind, randomized placebo-controlled study to evaluate the effects of dalcetrapib on CV risk in a genetically defined population with a recent Acute Coronary Syndrome
Principle Investigator: Ronald Fields, M.D., F.A.C.C.
Sponsor: DalCor

CLEAR Trial: (ENROLLMENT PENDING)

A randomized double-blind, parallel group, multicenter study to evaluate the efficacy and safety of Bempedoic Acid (ETC-1002) 180mg compared to placebo added to background lipid-modifying therapy in patients with elevated LDL-C who are statin intolerant.
Principle Investigator: Ronald Fields, M.D., F.A.C.C.
Sponsor: Esperion Therapeutics, Inc.